It’s a great pleasure to announce that today we are launching NANOBIOME to the market.

Thanks to the Nanobiome test it’s possible to characterize the bacterial environment of the gut and to assess their general condition. This launch is in line with the implementation of our company’s emission goal: comprehensive genomic and metagenomic databases creation. The NANOBIOME project is a key element of genXone’s development strategy.

First, scientific phase of the NANOBIOME project assumed the creation of a database collecting results of gut microbiome of healthy, adult people living in Poland. Such information will help to answer the question: does healthy gut microbiome exist,? And the base itself is also the very first set of information about the environment of
intestinal bacteria. We we found the correlation between the results of the microbiome and the reported ailments of the participants of the study as well as their diet and habits. The obtained statistics confirm that the condition of the intestines has a strong influence on health of every human being, and the type of diet may affect the susceptibility of the human body to many infections or diseases.

“Today we are delivering on our promises from the IPO period by bringing the NANOBIOME project into the commercial phase. Obtaining a reference database describing the gut microbiome in the country allowed us to obtain a satisfactory answer to the key question – what is the real impact of the gut microbiome on the human body? In the next step we’ve prepared a complete solution that today we cam offer in our sales network and in the network of our shareholder – Diagnostyka S.A.. The large-scale implementation of such a comprehensive microbiota study introduces very valuable information to the market, on the basis of which doctors or nutritionists will be able to conduct more effective and, most importantly, patient-specific therapies or dietary programs ”- emphasizes Michał Kaszuba, President of The Board of genXone.

Intestinal microbiota and health

The aim of the project from the very beginning was to develop the most effective and high-throughput tests of the gut microbiota that provide the most detailed assessment of the condition of the digestive system. The overriding goal of this project is to create extensive databases. Analysis of collected information will let us look at the issues of the gut microbiome from a broad perspective, thus creating a reliable tool to facilitate the work of the medical industry – gastroenterologists or nutrition specialists. Such information gathered in one place help to determine the relationship between specific disease entities and changes in the human microbiome.

“With our project, we prove that the gut microbial environment is associated with disease. The low biodiversity of the microbiome directly affects our immune system. In simple words: the fewer different bacteria we have, the less developed our immune system is, and our bacteria are able to undertake fewer tasks . Of course, we are aware that the creation of extensive databases allowing for drawing conclusions regarding the relationship between the microbiome and specific disease entities is a very long process, but we are ready for it “-
adds Michał Kaszuba.

Our company is one of the world leaders in conducting research using the nanopore sequencing method. It provides very high efficiency in the microorganisms analysis, Currently, the nanopore technology is the only one that allows obtaining infinitely long readings of nucleotide sequences. That’s why NANOBIOME tests allow you to obtain the most detailed information about the gut bacteria specificity.

Sales channels

The tests will be on sale in the company’s online store – nanobiome.pl and in the sales channels of Diagnostyka.